News from the BioCity Campus

Call for participation: Online survey on the Saxon research landscape

In an online survey, the Saxon State Ministry for Science, Culture and Tourism (SMWK) collects topics and priorities to strengthen regional science.

Make an active contribution and take part in the survey on the Saxon research landscape!

  • What are the key future issues that Saxon R&I policy must focus on?
  • How can the contribution of science to sustainable development in Saxony be strengthened?
  • What framework conditions are needed to advance the future-oriented expansion or further development of research infrastructure in Saxony?
  • What regional potential is there that can be built on?

Answers to these and many other questions are the focus of a strategy process initiated by the SMWK: project »White Paper for Research in Public Scientific Institutions in the Free State of Saxony«. The white paper lays the foundations for being able to accompany and help shape current research policy issues of the future and the central societal challenges associated with them.

For this purpose a online survey created, which should generate the broadest possible mood picture of the research landscape in Saxony. The insights to be gained from this will be condensed using participatory formats (workshops, interviews) and including extensive document and data analyzes and will ultimately lead to the development of the white paper. For more information see project profile.

Participation is possible until April 14, 2022 in German / English. The survey will take about 20 to 30 minutes. Your information will be evaluated anonymously.

Take the survey

previous news

With the reorganization of the Management Board, Vita 34 is setting the course for accelerated growth in new business areas

Vita 34 AG (ISIN: DE000A0BL849; WKN: A0BL84), Europe's leading cell bank, is laying the groundwork for accelerated growth in its core business with an extensive restructuring of its Management Board and accelerating development in its new business areas of cell-based drugs / viral vectors production ( CDMO) and cell therapies (CAR-T therapies).


c-LEcta reaches agreement to be acquired by Kerry Group

c-LEcta, a leading biotechnology company in the fields of enzyme engineering and bioprocess development, has entered into an agreement with the Kerry Group for the group to acquire a majority stake. Kerry is a leading global supplier of flavors and nutrients to the food, beverage and pharmaceutical industries.